Genomcore secures nearly 1 million euros in EU Next Generation funding to drive personalized medicine
Genomcore secures nearly one million euros in EU funding to deploy personalized medicine against metastatic cancer.
The Barcelona-based health data company has obtained 919,610 euros from the European Union's Next Generation funds to develop and implement advanced personalized medicine solutions. This significant investment will fuel the company's mission to transform how metastatic cancer is treated through data-driven, individualized approaches.
The project focuses on building technological infrastructure that enables healthcare institutions to harness genomic and biomedical data for more precise cancer diagnoses and treatment plans. By leveraging its BIMS (Biomedical Information Management System) platform, Genomcore aims to bridge the gap between raw patient data and actionable clinical insights, ultimately improving outcomes for patients battling metastatic cancer.
This funding reinforces Genomcore's position as a key player in Spain's precision medicine ecosystem and highlights the European Union's commitment to supporting innovative health technology companies through the Next Generation recovery programme.
